Johnson & Johnson FDA

US FDA approves new nasal spray for depression treatment

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

CNN on MSN · 1d

FDA approves standalone use of J&J’s ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

Popular Science · 1d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

FiercePharma2d

Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

US FDA approves new nasal spray for depression treatment

Trending now